CN114302879A - 选择性雌激素受体降解剂 - Google Patents
选择性雌激素受体降解剂 Download PDFInfo
- Publication number
- CN114302879A CN114302879A CN202080053315.6A CN202080053315A CN114302879A CN 114302879 A CN114302879 A CN 114302879A CN 202080053315 A CN202080053315 A CN 202080053315A CN 114302879 A CN114302879 A CN 114302879A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- cancer
- less
- difluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921029554 | 2019-07-22 | ||
| IN201921029554 | 2019-07-22 | ||
| PCT/IB2020/056914 WO2021014386A1 (en) | 2019-07-22 | 2020-07-22 | Selective estrogen receptor degrader |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114302879A true CN114302879A (zh) | 2022-04-08 |
Family
ID=71842730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080053315.6A Pending CN114302879A (zh) | 2019-07-22 | 2020-07-22 | 选择性雌激素受体降解剂 |
Country Status (15)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112638870A (zh) * | 2018-09-07 | 2021-04-09 | 赛诺菲 | 用于制备6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的方法 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12391667B2 (en) | 2019-07-22 | 2025-08-19 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases |
| US11014915B2 (en) * | 2019-07-22 | 2021-05-25 | Sun Pharma Advanced Research Company Limited | Selective estrogen receptor degrader |
| PE20241731A1 (es) * | 2022-02-01 | 2024-08-19 | Lilly Co Eli | Procesos para la preparacion de degradadores selectivos del receptor de estrogeno |
| CN119176799B (zh) * | 2024-09-19 | 2025-10-03 | 晨伫(杭州)生物科技有限责任公司 | 色烯衍生物及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013090829A1 (en) * | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| CN105451735A (zh) * | 2013-06-19 | 2016-03-30 | 西拉根制药公司 | 氮杂环丁烷雌激素受体调节剂和其用途 |
| CN107406433A (zh) * | 2014-12-18 | 2017-11-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的2,3‑二苯基色烯的衍生物 |
| CN108699021A (zh) * | 2015-10-27 | 2018-10-23 | 太阳医药高级研究有限公司 | 新的杂环抗雌激素 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| DE69023906T2 (de) | 1990-08-09 | 1996-04-11 | Council Scient Ind Res | Benzopyrane und Verfahren zu deren Herstellung. |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| US5407947A (en) | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
| US5389646A (en) | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
| AU8102398A (en) | 1997-07-09 | 1999-02-08 | Central Drug Research Institute | (dl)-2,3-diaryl-2h-1-benzopyrans |
| DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| BR112014014767A2 (pt) | 2011-12-16 | 2017-06-13 | Olema Pharmaceuticals Inc | novos compostos de benzopirano, composições e usos dos mesmos |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| CN103879283B (zh) * | 2014-03-10 | 2019-01-15 | 浙江吉利汽车研究院有限公司 | 一种电动车辆 |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| JP6768711B2 (ja) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
| US11014915B2 (en) * | 2019-07-22 | 2021-05-25 | Sun Pharma Advanced Research Company Limited | Selective estrogen receptor degrader |
-
2020
- 2020-07-22 US US16/936,022 patent/US11014915B2/en active Active
- 2020-07-22 JP JP2022504655A patent/JP2022541938A/ja active Pending
- 2020-07-22 BR BR112022001285A patent/BR112022001285A2/pt not_active IP Right Cessation
- 2020-07-22 AU AU2020317099A patent/AU2020317099A1/en not_active Abandoned
- 2020-07-22 CA CA3148592A patent/CA3148592A1/en active Pending
- 2020-07-22 CN CN202080053315.6A patent/CN114302879A/zh active Pending
- 2020-07-22 WO PCT/IB2020/056914 patent/WO2021014386A1/en not_active Ceased
- 2020-07-22 MX MX2022001013A patent/MX2022001013A/es unknown
- 2020-07-22 EP EP20747136.8A patent/EP4003525A1/en not_active Withdrawn
- 2020-07-22 KR KR1020227005904A patent/KR20220046586A/ko not_active Ceased
- 2020-07-22 PE PE2022000135A patent/PE20221588A1/es unknown
- 2020-07-22 PH PH1/2022/550182A patent/PH12022550182A1/en unknown
-
2021
- 2021-05-05 US US17/308,501 patent/US20210261534A1/en not_active Abandoned
-
2022
- 2022-01-22 CL CL2022000156A patent/CL2022000156A1/es unknown
- 2022-01-23 IL IL290036A patent/IL290036A/en unknown
- 2022-01-25 ZA ZA2022/01157A patent/ZA202201157B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013090829A1 (en) * | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| CN105451735A (zh) * | 2013-06-19 | 2016-03-30 | 西拉根制药公司 | 氮杂环丁烷雌激素受体调节剂和其用途 |
| CN107406433A (zh) * | 2014-12-18 | 2017-11-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的2,3‑二苯基色烯的衍生物 |
| CN108699021A (zh) * | 2015-10-27 | 2018-10-23 | 太阳医药高级研究有限公司 | 新的杂环抗雌激素 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112638870A (zh) * | 2018-09-07 | 2021-04-09 | 赛诺菲 | 用于制备6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的方法 |
| CN112638870B (zh) * | 2018-09-07 | 2025-04-25 | 赛诺菲 | 用于制备6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202201157B (en) | 2023-07-26 |
| JP2022541938A (ja) | 2022-09-28 |
| CA3148592A1 (en) | 2021-01-28 |
| BR112022001285A2 (pt) | 2022-03-22 |
| WO2021014386A1 (en) | 2021-01-28 |
| PE20221588A1 (es) | 2022-10-10 |
| MX2022001013A (es) | 2022-02-22 |
| US20210261534A1 (en) | 2021-08-26 |
| KR20220046586A (ko) | 2022-04-14 |
| US20210024504A1 (en) | 2021-01-28 |
| IL290036A (en) | 2022-03-01 |
| AU2020317099A1 (en) | 2022-02-24 |
| PH12022550182A1 (en) | 2022-11-14 |
| US11014915B2 (en) | 2021-05-25 |
| EP4003525A1 (en) | 2022-06-01 |
| CL2022000156A1 (es) | 2022-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11014915B2 (en) | Selective estrogen receptor degrader | |
| US11672785B2 (en) | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | |
| US9115091B2 (en) | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | |
| CN1181077A (zh) | 苯并吡喃类化合物及其使用方法 | |
| TW201710253A (zh) | 抗雌激素化合物 | |
| KR20140107371A (ko) | 6,7-디히드로-5h-벤조[7]아눌렌 유도체, 그의 제조 방법, 상기 6,7-디히드로-5h-벤조[7]아눌렌 유도체를 함유하는 제약 제제, 및 약물을 제조하기 위한 그의 용도 | |
| WO2009120999A2 (en) | Use of an endoxifen prodrug for treatment of breast cancer | |
| Bai et al. | Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities | |
| WO2024054845A1 (en) | Macrocycic compounds, compositions, and methods of using thereof | |
| JP2025523065A (ja) | アゾポドフィロトキシン誘導体su056のエナンチオマー | |
| WO2011129837A1 (en) | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer | |
| US7632963B2 (en) | Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate | |
| KR20210134306A (ko) | 아크릴-함유 핵 수출 조절제들 및 이들의 용도들 | |
| EP4577542A1 (en) | Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof | |
| WO2004031125A1 (ja) | スピロ化合物、それを含有する医薬組成物及び該化合物の中間体 | |
| JP2025531033A (ja) | 新規の置換2-カルボニル-ベンゾチオフェン-6-カルボン酸誘導体、それらの調製のためのプロセス及びその治療的使用 | |
| CN119790048A (zh) | 新颖的取代的四氢异喹啉-6-甲酸衍生物、用于其制备的方法及其治疗用途 | |
| JP5054882B2 (ja) | テトラヒドロベンズフルオレン誘導体 | |
| RU2855858C2 (ru) | ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА | |
| EP1171133B1 (en) | R-hydroxynefazodone | |
| Vedavi et al. | Exploration of new 5-chloro-7-iodo quinoline core analogues as anti-pancreatic cancer hits targeting MIA PaCa-2: EGFR inhibition | |
| CN115819407A (zh) | 一种Ensitrelvir类似物及其制备方法和抗新冠用途 | |
| HK1124337A (en) | Nuclear receptor binding agents | |
| KR20220129447A (ko) | 트랜스글루타미나제-2 활성 억제용 신규 화합물 및 이를 함유하는 암 예방 또는 치료용 조성물 | |
| WO2016022325A1 (en) | Novel triarylethylene compounds and methods using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220408 |
|
| WD01 | Invention patent application deemed withdrawn after publication |